Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC decreased its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 5.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the company’s stock after selling 370 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Apogee Therapeutics were worth $384,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. AlphaCentric Advisors LLC purchased a new stake in Apogee Therapeutics during the 3rd quarter worth approximately $499,000. China Universal Asset Management Co. Ltd. increased its stake in Apogee Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,655 shares of the company’s stock worth $508,000 after buying an additional 3,371 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after buying an additional 285 shares in the last quarter. Waypoint Capital Advisors LLC purchased a new stake in Apogee Therapeutics during the 3rd quarter worth approximately $36,835,000. Finally, Handelsbanken Fonder AB increased its stake in Apogee Therapeutics by 25.7% during the 3rd quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock worth $517,000 after buying an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Insider Activity

In related news, CEO Michael Thomas Henderson sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $47.62, for a total value of $1,904,800.00. Following the transaction, the chief executive officer now directly owns 1,394,487 shares in the company, valued at approximately $66,405,470.94. This represents a 2.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Jane Henderson sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $48.26, for a total value of $289,560.00. Following the completion of the transaction, the chief financial officer now owns 200,871 shares in the company, valued at $9,694,034.46. This represents a 2.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 120,995 shares of company stock worth $6,417,855 over the last ninety days. Corporate insiders own 36.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wedbush reiterated an “outperform” rating and set a $87.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday, November 12th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $78.50.

Apogee Therapeutics Price Performance

APGE stock opened at $47.25 on Monday. The business has a 50 day simple moving average of $54.78 and a 200-day simple moving average of $48.98. The firm has a market capitalization of $2.13 billion, a PE ratio of -19.52 and a beta of 2.93. Apogee Therapeutics, Inc. has a 1 year low of $16.39 and a 1 year high of $72.29.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.